Cover Image

A nonviral, nonintegrating DNA nanovector platform for the safe, rapid, and persistent manufacture of recombinant T cells

The compelling need to provide adoptive cell therapy (ACT) to an increasing number of oncology patients within a meaningful therapeutic window makes the development of an efficient, fast, versatile, and safe genetic tool for creating recombinant T cells indispensable. In this study, we used noninteg...

Full description

Saved in:
Bibliographic Details
Main Authors: Bozza, Matthias (Author) , De Roia, Alice (Author) , Correia, Margareta (Author) , Berger, Aileen (Author) , Tuch, Alexandra (Author) , Schmidt, Andreas (Author) , Zörnig, Inka (Author) , Jäger, Dirk (Author) , Schmidt, Patrick (Author) , Harbottle, Richard P. (Author)
Format: Article (Journal)
Language:English
Published: 14 April 2021
In: Science advances
Year: 2021, Volume: 7, Issue: 16, Pages: 1-13
ISSN:2375-2548
DOI:10.1126/sciadv.abf1333
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1126/sciadv.abf1333
Get full text
Author Notes:Matthias Bozza, Alice De Roia, Margareta P. Correia, Aileen Berger, Alexandra Tuch, Andreas Schmidt, Inka Zörnig, Dirk Jager, Patrick Schmidt, Richard P. Harbottle
Description
Summary:The compelling need to provide adoptive cell therapy (ACT) to an increasing number of oncology patients within a meaningful therapeutic window makes the development of an efficient, fast, versatile, and safe genetic tool for creating recombinant T cells indispensable. In this study, we used nonintegrating minimally sized DNA vectors with an enhanced capability of generating genetically modified cells, and we demonstrate that they can be efficiently used to engineer human T lymphocytes. This vector platform contains no viral components and is capable of replicating extrachromosomally in the nucleus of dividing cells, providing persistent transgene expression in human T cells without affecting their behavior and molecular integrity. We use this technology to provide a manufacturing protocol to quickly generate chimeric antigen receptor (CAR)-T cells at clinical scale in a closed system and demonstrate their enhanced anti- tumor activity in vitro and in vivo in comparison to previously described integrating vectors.
Item Description:Gesehen am 04.06.2021
Physical Description:Online Resource
ISSN:2375-2548
DOI:10.1126/sciadv.abf1333

Similar Items